Poseida Therapeutics, Inc.

NasdaqGS:PSTX Stock Report

Market Cap: US$286.6m

Poseida Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Kristin Yarema

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure2.3yrs
Board average tenure2.9yrs

Recent management updates

Recent updates

Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%

Apr 09
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%

Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement

Mar 17

Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Jan 24
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too

Dec 18
Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too

New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Aug 13
New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding

Apr 17
Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding

Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech

Sep 04

Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M

Aug 11

Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B

Aug 03

Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

May 15
Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

Poseida Therapeutics: Genome Engineering For Safer Cell Therapies

Oct 30

What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?

Mar 19
What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?

Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?

Jan 25
Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?

Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow

Dec 09

FDA lifts clinical hold on Poseida's prostate cancer cell therapy study

Nov 02

CEO

Kristin Yarema (51 yo)

less than a year

Tenure

Dr. Kristin Yarema Ph.D. is President & CEO of Poseida Therapeutics, Inc. from January 01, 2024 and serves as its Director since January 2024. Dr. Yarema, was the Chief Commercial Officer and Senior Vice P...


Leadership Team

NamePositionTenureCompensationOwnership
Mark Gergen
Executive Chairman of the Board6.3yrsUS$4.37m0.15%
$ 432.2k
Harry Leonhardt
General Counsel3.8yrsUS$978.34k0.041%
$ 116.8k
Kristin Yarema
Presidentless than a yearno datano data
Johanna Mylet
Chief Financial Officer3.8yrsno data0.074%
$ 210.7k
Loren Wagner
Chief Operations Officer2.3yrsno datano data
Kristin Martin
Chief People & Administration Officer5.3yrsno datano data
Alexander Chapman
Senior VP of Investor Relations & Corporate Communicationsless than a yearno datano data
Devon Shedlock
Chief Scientific Officer of Cell Therapy4.2yrsno datano data
Lisa Portale
Senior Vice President of Regulatory Affairs2.5yrsno datano data
Jeffrey W. Winkelman
Senior VP & Chief Patent Counsel2.3yrsno datano data
Karen Basbaum
Senior Vice President of Business Development2.3yrsno datano data
Syed Rizvi
Chief Medical Officerno datano datano data

2.3yrs

Average Tenure

56yo

Average Age

Experienced Management: PSTX's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mark Gergen
Executive Chairman of the Board6.3yrsUS$4.37m0.15%
$ 432.2k
Kristin Yarema
Presidentless than a yearno datano data
John Schmid
Lead Independent Director5.8yrsUS$159.54k0.020%
$ 58.3k
Carl June
Chairman of Cell Therapy Scientific Advisory Board3.1yrsno datano data
George Church
Chairman of Gene Therapy Scientific Advisory Board1.8yrsno datano data
Marcea Lloyd
Independent Director5.3yrsUS$133.54k0.031%
$ 88.1k
Cynthia Collins
Independent Director2.8yrsUS$136.16k0.020%
$ 58.3k
Charles Baum
Independent Director1.9yrsUS$194.91k0.014%
$ 38.9k
Luke Corning
Independent Director3.3yrsUS$124.54k0.020%
$ 58.3k
Luca Gattinoni
Member of Scientific Advisory Board2.9yrsno datano data
Christine Brown
Member of Scientific Advisory Board2.9yrsno datano data
Jan Joseph Melenhorst
Member of Scientific Advisory Board2.9yrsno datano data

2.9yrs

Average Tenure

65yo

Average Age

Experienced Board: PSTX's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.